
CITATION REPORT List of articles citing



DOI: 10.1097/meg.0b013e3283479125 European Journal of Gastroenterology and Hepatology , 2011, 23, 603-6.

Source: https://exaly.com/paper-pdf/50708498/citation-report.pdf

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper Paper	IF	Citations
24	Anti-tumor necrosis factor-Imonoclonal antibody alleviates parenteral nutrition-associated liver disease in mice. <i>Journal of Parenteral and Enteral Nutrition</i> , 2012 , 36, 219-25	4.2	19
23	Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 857-9	2.2	4
22	Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 725-35	6.1	43
21	Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 649-57	2.4	15
20	Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. <i>Journal of Crohnts and Colitis</i> , 2012 , 6, 143-53	1.5	75
19	Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 864-72	4.5	53
18	Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1829-	-343	61
17	Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. <i>Clinical Immunology</i> , 2013 , 149, 73-82	9	14
16	Nonneoplastic diseases of the small intestine: differential diagnosis and Crohn disease. <i>American Journal of Roentgenology</i> , 2013 , 201, W174-82	5.4	6
15	Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohnts and Colitis, 2015, 9, 806-15	1.5	120
14	Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 60-70	4.5	28
13	Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 99-107	6.1	8
12	Review of pulmonary adverse effects of infliximab therapy in Crohn's disease. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 769-75	4.1	8
11	Neurological Complications of Gastrointestinal Disease. Seminars in Pediatric Neurology, 2017 , 24, 43-53	3 2.9	3
10	Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1689-1701	4.5	14
9	Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 433-439	4.5	9
8	Twenty years of biological therapy in an patient with IBD. BMJ Case Reports, 2018, 2018,	0.9	

CITATION REPORT

7	Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions. <i>Pediatric Quality & Safety</i> , 2019 , 4, e137	1	
6	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohnts and Colitis</i> , 2021 , 15, 840-859	1.5	11
5	Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017. <i>JAMA Network Open</i> , 2021 , 4, e2110268	10.4	2
4	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. 2013, 345-355		
3	Cholangiocarcinoma in Patients with Crohn® Disease. <i>Journal of Cancer Therapy</i> , 2015 , 06, 21-24	0.2	
2	Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery <i>Scandinavian Journal of Gastroenterology</i> , 2022 , 1-9	2.4	O
1	Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review. 14,		0